The U.S. Food and Drug Administration (FDA) recently announced the appointment of Geoffrey Kim, MD, as Director of the Division of Oncology Products 1 (DOP1) in the Office of Hematology Oncology Products. Dr. Kim assumed this position effective March 22, 2015.
Dr. Kim previously served as the Acting Deputy Director in Division of Oncology Products 1. He was involved with numerous cross-center working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and dose finding optimization strategies for oncology products.
Dr. Kim is also the gynecologic malignancies scientific liaison for Office of Hematology Oncology Products, and he is active with outreach to the ovarian cancer community through the Society for Gynecologic Oncologists, Gynecologic Oncology Group, and the Ovarian Cancer National Alliance. Dr. Kim began working at the FDA in 2010 as a Medical Officer in Division of Oncology Products 1.
He received his bachelor’s degree at UCLA, his medical degree at the New York Medical College, and completed his residency in internal medicine at the Montefiore Medical Center. He performed laboratory research at these institutions with a particular focus on cell adhesion molecules and cellular signaling. Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in the NCI molecular signaling section and the ovarian cancer clinic.
Amna Ibrahim, MD, served as Acting Division Director of Division of Oncology Products 1 during the transition period. Dr. Ibrahim will assume her previous role as the Deputy Division Director of Division of Oncology Products 1. ■
